{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-26-000052","form_type":"8-K/A","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2026-09-16T20:06:13+00:00","discovered_at":"2026-09-16T20:07:10.465540+00:00","generated_at":"2026-09-16T20:07:20.863725+00:00","sec_items":["9.01","2.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CareDx files Naveris 2025 financials: revenue $34.3M, net loss $3.9M, going concern doubt","bullets":["Naveris FY2025 revenue $34.337M; net loss $3.882M; accumulated deficit $65.049M.","Substantial doubt about going concern; recurring operating losses and negative operating cash flow.","Cash and equivalents $15.401M plus restricted cash $0.890M at Dec 31, 2025.","Naveris is commercial-stage precision oncology; NavDx TTMV-HPV DNA test for viral-induced cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-26-000052","json":"https://secwatch.observer/filing/0001217234-26-000052.json","markdown":"https://secwatch.observer/filing/0001217234-26-000052.md","text":"https://secwatch.observer/filing/0001217234-26-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000052/0001217234-26-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000052/cdna-20260630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T20:07:20.863725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}